HOME >> MEDICINE >> NEWS
Outpatient setting very safe for skin cancer surgery

Durham, N.C. -- Mohs micrographic surgery, a common technique used to remove skin cancers, is very safe when performed in an outpatient setting, according to a study published in the Feb. 17, 2003, issue of the Archives of Dermatology. The researchers said their results counter the arguments of legislators, lobbyists and others who question the overall safety of outpatient surgeries.

"It is concerning as a physician to see lobbyists and policy makers openly criticize medical practice without the benefit of data to support their arguments," said study lead author Jonathan Cook, M.D., director of dermatologic surgery at Duke University Medical Center.

The study, conducted by Cook and resident physician Jennifer Perone, M.D., assessed rates of complications associated with 1,343 outpatient Mohs procedures performed at Duke during 2000. The overall complication rate was 1.64 percent, or 22 complications out of the 1,343 surgeries. Thus, said the researchers, the complication rate is low enough to conclude that performing Mohs surgery on an outpatient basis does not represent an undue risk.

Mohs surgery, also known as microscopically controlled surgery, was developed by Frederic Mohs, M.D. for the treatment of certain skin cancers. Performed under local anesthesia, the technique combines surgical removal of the skin cancer with immediate microscopic examination of the removed tissue in order to identify any residual cancerous tissue. The surgeon continues the process of removing tissue and studying it under the microscope until all cancer has been removed. Typically, the surgeon then reconstructs the surgical wound by using a variety of repair techniques.

The Mohs technique has the highest cure rate of all skin cancer treatment methods, and involves the surgical removal of the least amount of tissue possible in order to adequately treat the cancer.

"Of course, any surgical procedure has to be performed in a supervised setting," sa
'"/>

Contact: Laura Sawyer Brinn or Amy Austell
laura.brinn@duke.edu
919-684-4148
Duke University Medical Center
17-Feb-2003


Page: 1 2 3

Related medicine news :

1. Outpatient lung cancer procedure promising for inoperable disease
2. Outpatient procedure shrinks benign breast lumps
3. Outpatient pediatric visits good opportunity to help parents quit smoking
4. Outpatient treatment shrinks liver tumors to acceptable size for laser procedure
5. Outpatient treatment is as effective as inpatient treatment for PID
6. Study: Dementia often undiagnosed in clinical settings
7. Risks of outpatient surgery vary with patient characteristics, surgical setting
8. U of MN study first to detect tobacco-specific carcinogens in non-smokers in public setting
9. Study suggests radiography unnecessary to identify TB in HIV pts in some settings
10. NIDA leads research network to improve substance abuse treatment in criminal justice settings
11. Vitamin C may help juice up metabolism in older adults, offsetting weight gain

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Outpatient setting very safe for skin cancer surgery

(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: